Expanded Analogues of dG and dC
subjected to N6 protection. An 840 mg (2.54 mmol) portion of
this intermediate was coevaporated with anhydrous pyridine
(3 × 5 mL) and then was suspended in 30.0 mL of anhydrous
pyridine, followed by addition of TMSCl (4.2 mL, 32.6 mmol).
After 30 min of stirring, the reaction solution was treated with
isobutyric anhydride (0.83 mL, 5.27 mmol). After being stirred
at room temperature for 24 h, the reaction was cooled to 0 °C
and treated with 5.0 mL of water. After 5 min, 5.0 mL of 25%
ammonium hydroxide was added. After an additional 15 min
stirring at 0 °C, volatiles were removed by evaporation. The
product was purified in nearly quantitative yield by silica gel
column chromatography (10-20% MeOH in CH2Cl2): 1H NMR
(CD3OD, 500 MHz) δ 8.78 (s, 0.4H), 8.70 (s, 0.6H), 8.54 (s,
0.4H), 8.49 (s, 0.6H), 7.83 (s, 0.6H), 7.81 (s, 0.4H), 6.06 (d, 0.4H,
J ) 7.0 Hz), 6.02 (d, 0.6H, J ) 7.5 Hz), 4.51-4.48 (m, 1H),
4.32-4.29 (m, 1H), 4.18-4.15 (m, 1H), 3.93-3.87 (m, 1H),
3.84-3.79 (m, 1H), 2.75-2.72 (m, 1H), 1.24 (d, 1H, J ) 8.5
Hz); 13C NMR (DMSO-d6, 125 MHz) δ 181.0, 180.9, 149.8,
147.7, 146.7, 142.6, 138.9, 132.1, 117.5, 116.6, 116.3, 109.3,
89.6, 86.48, 86.2, 84.1, 74.7, 74.4, 70.8, 70.7, 61.9, 61.7, 35.5,
19.7; HRMS calcd for C18H22N5O6 (M + H) 404.1570, found
404.1575.
3′,5′-Tetraisopropyldisiloxane-Protected [N6-Isobutyryl-
6-amino-3,7-dihydroimidazo[4,5-g]quinazolin-8-one]-1′-
â-D-ribofuranoside (Regioisomers 16a and 16b). The
amine-protected riboside mixture 15a,b (496 mg, 1.23 mmol)
and imidazole (300 mg) were dissolved in 20.0 mL of anhydrous
DMF, to which was added 481 µL (1.48 mmol) of 1,3-dichloro-
1,1,3,3-tetraisopropylsiloxane. After being stirred at room
temperature for 24 h, the solvent was removed by evaporation.
The residue was dissolved in 250 mL of ether. After being
washed with 125 mL of water and 125 mL of aqueous
saturated NaHCO3, the organic phase was dried over NaSO4,
filtered, concentrated, and purified by silica gel column chro-
matography (50-100% EtOAc in hexanes). A white solid was
obtained as product in 71% yield (560 mg): 1H NMR (CDCl3,
500 MHz) δ 12.00 (s, 0.5H), 11.93 (s, 0.5H), 8.75 (s, 0.5H), 8.47
(s, 0.5H), 8.42 (s, 0.5H), 8.39 (s, 0.5H), 7.95 (s, 0.5H), 7.54 (s,
0.5H), 6.03 (s, 0.5H), 5.99 (s, 0.5H), 4.60-4.55 (m, 1H), 4.34-
4.20 (m, 3H), 4.16-4.12 (m, 1H), 3.32 (s, 1H), 3.129 (s, 1H),
2.72-2.67 (m, 1H), 1.34-1.27 (m, 6H), 1.14-0.99 (m, 28H);
13C NMR (CDCl3, 125 MHz) δ 170.7, 170.6, 170.0, 169.9, 169.8,
169.7, 149.3, 145.3, 144.0, 142.5, 137.9, 131.5, 119.4, 117.2,
116.7, 108.9, 87.5, 87.1, 80.9, 80.4, 73.5, 73.2, 70.7, 70.2, 63.2,
62.9, 36.6, 21.1, 21.0, 20.9, 20.8, 20.7, 20.7, 19.3, 19.3; HRMS
calcd for C30H47N5O7Si2 (M + H) 646.3087, found 646.3082.
3′,5′-Tetraisopropyldisiloxane-Protected [N6-Isobutyryl-
6-amino-3,7-dihydroimidazo[4,5-g]quinazolin-8-one]-1′-
â-D-Ribofuranoside-2′-O-thiocarbonate Phenyl Ester (17).
Starting material 16a,b (859 mg, 1.33 mmol) and DMAP (974
mg, 7.98 mmol) were dissolved in 40 mL of anhydrous CH3CN,
to which was added phenyl chlorothionoformate (368 µL, 2.66
mmol). After being stirred at room temperature 24 h, the
reaction mixture was evaporated to dryness. The residue was
dissolved in 120 mL of EtOAc, and the organic phase was
washed with saturated NaHCO3 (60 mL) and brine (60 mL).
After being dried over NaSO4, the organic layer was concen-
trated and purified by silica gel column chromatography (25-
50-67% EtOAc in hexanes). Separation of imidazole regio-
isomers was successful in this step. The desired product (17)
was obtained as a pale yellow foamy solid in 50% yield (516
mg): 1H NMR (CDCl3, 500 MHz) δ 11.99 (s, 1H), 8.67 (s, 1H),
8.72 (b, 1H), 8.51 (s, 1H), 7.59 (s, 1H), 7.463 (t, 2H, J ) 7.5
Hz), 7.35 (t, 1H, J ) 7.0 Hz), 7.179 (d, 2H, J ) 8.0 Hz), 6.21
(s, 1H), 6.03 (d, 1H, 7.0 Hz), 4.84-4.81 (m, 1H), 4.36-4.33 (m,
1H), 4.28-4.26 (m, 1H), 4.26-4.12 (m, 1H), 2.67-2.65 (m, 1H),
1.28 (d, 6H, J ) 7.0 Hz), 1.16-1.00 (m, 28H); 13C NMR (CDCl3
125 MHz) δ 194.1, 178.6, 162.2, 153.6, 145.38, 144.9, 143.6,
142.8, 137.8, 129.9, 127.2, 121.9, 121.2, 119.6, 117.0, 105.9,
87.8, 84.2, 82.7, 68.6, 60.7, 60.2, 36.9, 19.3, 17.7, 17.6, 17.6,
17.6, 17.3, 17.20, 17.2, 17.0, 14.5, 13.64, 13.2, 13.0; HRMS calcd
for C37H52N5O8Si2S (M + H) 782.3070, found 782.3058.
The other regioisomer was eluted from the silica column
with 100% EtOAc in 21% yield (214 mg).
3′,5′-Tetraisopropyldisiloxane-Protected [N6-Isobutyryl-
6-amino-3,7-dihydroimidazo[4,5-g]quinazolin-8-one]-1′-
â-D-2′-deoxyribofuranoside (18). Starting material 17 (480
mg, 0.61 mmol) and AIBN (45 mg) were dissolved in 18.0 mL
of toluene, to which was added 2.0 mL of n-Bu3SnH. After
being heated at reflux for 2 h, the reaction mixture was cooled.
Volatiles were removed by evaporation, and compound 18 was
purified by silica gel column chromatography (50-75% EtOAc
in hexanes). The product was obtained as a white foamy solid
in 71% yield (276 mg): 1H NMR (CDCl3 500 MHz) δ 12.04 (s,
1H), 8.75 (s, 1H), 8.35 (s, 1H), 7.47 (s, 1H), 6.24 (dd, 1H, J )
3.5, 7.0 Hz), 4.73-4.72 (m, 1H), 4.12-3.97 (m, 3H), 2.70-2.65
(m, 2H), 2.61-2.59 (m, 1H), 1.32 (d, 6H, J ) 6.5 Hz), 1.12-
0.99 (m, 28H); 13C NMR (CDCl3 125 MHz) δ 178.5, 162.2, 145.3,
144.5, 143.8, 142.9, 138.1, 119.5, 116.6, 85.6, 84.1, 69.9, 61.8,
40.2, 36.9, 19.3, 17.8, 17.7, 17.6, 17.4, 17.3, 17.1, 13.7, 13.4,
13.2, 12.7; HRMS cald. for C30H48N5O6Si2 (M + H) 630.3138,
found 630.3182.
[N6-Isobutyryl-6-amino-3,7-dihydroimidazo[4,5-g]-
quinazolin-8-one]-1′-â-D-2′-deoxyribofuranoside (19). Start-
ing material 18 (276 mg, 0.44 mmol) was dissolved in 12.0 mL
of anhydrous THF and 4.0 mL of anhydrous pyridine, to which
was added 70% HF in pyridine (350 µL). After the reaction
mixture was stirred at room temperature for 80 h, it was
concentrated and purified by silica gel column chromatography
(10-20% MeOH in CH2Cl2). The product was obtained as a
white solid in essentially quantitative yield: 1H NMR (CD3OD,
500 MHz) δ 11.98 (s, 1H), 11.51 (s, 1H), 8.68 (s, 1H), 8.33 (s,
1H), 7.71 (s, 1H), 6.45 (t, 1H, J ) 7.0 Hz), 5.41 (d, 1H, J ) 4.0
Hz), 5.01 (t, 1H, J ) 5.0 Hz), 4.44-4.42 (m, 1H), 3.89 (q, 1H,
J ) 4.0 Hz), 3.61-3.54 (m, 2H), 2.81-2.78 (m, 1H), 2.67-2.62
(m, 1H), 2.37-2.33 (m, 1H), 1.13 (d, 6H, J ) 6.5 Hz); 13C NMR
(DMSO-d6, 125 MHz) δ 181.0, 161.6, 146.5, 146.2, 144.9, 142.6,
139.0, 117.5, 116.2, 107.1, 88.3, 85.4, 71.1, 62.1, 35.5, 19.7;
HRMS calcd for C18H22N5O5 (M + H) 388.1621, found 388.1631.
Base-Protected Phosphoramidite Derivative of 19.
Synthetic details and characterization are given in the Sup-
porting Information.
Synthesis of dxC Nucleoside.
3′,5′-Diacetyl-1′-â-[8-(6-methylquinazoline-2, 4-dione)]-
D-2′-deoxyribofuranoside (4). 1′-â-[8-(6-Methylquinazoline-
2, 4-dione)]-2′-D-deoxyribofuranose 37 (200 mg, 0.69 mmol) was
dissolved in 5 mL of dry pyridine. To the solution was added
200 µL of acetic anhydride. The mixture was stirred at room
temperature for 8 h. Volatiles were removed under vacuum,
and crude product was purified by silica column chromatog-
raphy (hexanes/ethyl acetate 1:1 followed by hexanes/ethyl
acetate 1:2) to give the product as a white foam (195 mg,
76%): 1H NMR (CDCl3, 500 MHz), δ) 9.74 (S, 1H), 9.39 (s,
1H), 7.93 (s, 1H), 7.28 (s, 1H), 5.26 (m, 2H), 4.52 (m, 1H), 4.33
(m, 2H), 2.38 (s, 3H), 2.40-2.29 (m, 2H), 2.21 (s, 3H), 2.15 (s,
3H); 13C NMR (CDCl3, 125.7 MHz) δ 171.3, 170.9, 163.3, 150.2,
136.5.06, 133.0, 128.3, 123.9, 116.0, 83.9, 80.7, 75.6, 64.0, 39.7,
21.3, 21.2, 20.8; HRMS (EI+) calcd for C18H21N2O7 [M + H]+
m/z ) 377.1349, found 377.1349.
3′,5′-Diacetyl-1′-â-[8-(6-methyl-4-thio-2-quinazolone)]-
D-2′-deoxyribofuranoside (5). Compound 4 (70 mg, 0.19
mmol) and phosphorus pentasulfide (211 mg, 0.95 mmol) were
charged into a round-bottom flask equipped with condenser.
Four milliliters of dry pyridine was added to form a suspension,
which turned into a clear solution upon heating to reflux. TLC
showed the reaction was complete after 4 h. Solvent was
removed under vacuum, and the residue was suspended in 15
mL of warm water. The aqueous suspension was extracted
with 3 × 20 mL dichloromethane. The organic layer was
collected, dried, and concentrated. Silica column chromatog-
raphy (hexanes/ethyl acetate 1:1) gave product 5 as yellow
foam (56 mg, 77%): 1H NMR (CDCl3, 500 MHz) δ 10.74 (s,
1H), 9.62 (s, 1H), 8.33 (s, 1H), 7.29 (s, 1H), 5.25 (m, 2H), 4.52
(m, 1H), 4.34 (m, 2H), 2.40 (s, 3H), 2.36 (m, 1H), 2.30 (m, 1H),
J. Org. Chem, Vol. 70, No. 2, 2005 641